Anteris Technologies Global Corp. · NASDAQ:AVR
Anteris Technologies Global — Shareholder Meeting (May 2022)
81 slides from Anteris Technologies Global's shareholder meeting presentation, May 25, 2022
Slide 1: Anteris 2021 AGM CEO Presentation
ANTERIS 2021 AGM CEO PRESENTATION May 25th 2022 www.anteristech.com | Follow us @anteristech Copyright Anteris Technologies Ltd 2021
Slide 2: Disclaimer
Disclaimer This presentation contains general information which is current as at 25 May 2022. It is information given in summary form and does not purport to be complete. Information in this presentation is not intended to be relied upon as advice to investors or potential investors and does not tak
Slide 3: 2016 to 2019
2016 a~ 2019
Slide 4: Agenda
Agenda • Financials • Competitive advantage • First in Human study • Market opportunity • Partnerships • Future revenues • Questions
Slide 5: 2021 A year of headlines
2021 A year of headlines
Slide 6: Ba oor .ce devoted to his queen, dead at
Ba oor .ce devoted to his queen, dead at 99
Slide 7: PUNTER'S WHO'S OFF
PUNTER'S WHO'S OFF LAST STAND THE LIST DETAILS > SPORT 5 ERFUL >Pi8, 19 FROG STRUCK DOWN BY LIGHTNING .. and a few hum ly hit too >>P2 TERRITORY SCHOOL ARDS) PAGE 3 a
Slide 8: Slide 8
Slide 9: Anteris made a few of its own headlines
Anteris made a few of its own headlines
Slide 10: Major milestones were achieved in 2021
Major milestones were achieved in 2021 AUGUST OCTOBER Close $8.82 Close $8.50 APRIL Extended Manufacturing Key Animal Study for EFS Close $9.85 Agreement (LeMaitre) Submission Completed FEBRUARY JUNE Close $7.11 ComASUR™ Key Milestone Key Partnerships with Close $6.80 IQVIA & CRF and Piper DECEMBER
Slide 11: DurAVR studies progressed rapidly in 2021 from animals to humans
DurAVR™ studies progressed rapidly in 2021 from animals to humans Animal lab Dr Hamid performing echo Dr Meduri implanting DurAVR™ being deployed DurAVR™
Slide 12: 2021 Financials
Equity statement ¢ ent 7 1,774,576
Slide 13: Financial highlights 2021
Financial highlights 2021 13
Slide 14: Anteris market cap increased by 515% in 2021
Anteris market cap increased by 515% in 2021 Key financial metrics FY2020 FY2021 • 10% increase in ADAPT® sales Actual Actual $m $m • Overall increase in expenses primarily reflects increased research and development Sales revenue 7.1 7.8 expenditure relating to the Group’s Transcatheter Aortic Valv
Slide 15: Focused investment in R&D has accelerated progress
Focused investment in R&D has accelerated progress Research & Development $19.5M Corporate & Operational $3.4M • DurAVRTM valve development program • Capital raising costs • Tblisi first-in-human trials • Company compliance costs • Design of the TAVR delivery system • Insurance • Regulatory and Medi
Slide 16: Operational costs remain stable 20/21
Operational costs remain stable 20/21 $25.0 M $22.9 M $20.0 M $19.5 M • Corporate + operational costs stable from 2020 to 2021 $15.3 M $15.0 M • R&D costs increased as we $12.2 M entered human studies $10.0 M $5.0 M $0.0 M 2020 2021 Project (TAVR) result Group result 16
Slide 17: Increasing CardioCel production with decreasing costs
Increasing CardioCel™ production with decreasing costs 2020: 20,589 units • 77% increase in units • 23% increase in costs 15,644 units 2021: • 32% increase in units • 2% decline in costs 8,850 units 2019 2020 2021 Total costs ($) Units 17
Slide 18: Highly productive workforce
Highly productive workforce TOTAL EMPLOYEE NUMBERS DIVERSITY 2021 FEMALE MALE 2020 2019 47% 46% 47% 53% 54% 53% 91 42 44 51 FY 16 Dec 19 Dec 20 Dec 21 18
Slide 19: Increased cash balance from equity and non dilutive sources
Increased cash balance from equity and non dilutive sources $40.0 M Perceptive investment $30.0 M LeMaitre sale of distribution rights $20.0 M Exercise of Rights unlisted options issue $10.0 M $0.0 M Mar-18 Sep-18 Mar-19 Sep-19 Mar-20 Sep-20 Mar-21 Sep-21 Mar-22 Cash (including term deposits) Operat
Slide 20: Increasing share price and company valuation
Increasing share price and company valuation $250 M $17.00 $18.00 $15.96 $16.00 $12.96 $230.8 M $200 M $217.4 M $14.00 $12.00 $150 M $10.00 $10.00 $143.8 M $6.80 $8.00 $100 M $6.20 $6.00 $4.90 $6.00 $3.75 $4.00 $50 M $59.1 M $47.2 M $36.6 M $2.00 $35.4 M $29.0 M $23.4 M $0 M $0.00 Dec 2018 Jun 2019
Slide 21: AVR has returned 141% since the CardioCel divestiture
AVR has returned 141% since the CardioCel™ divestiture • The S&P/ASX Emerging Companies Index (XEC) is a benchmark consisting of 200 Australian microcap AVR return XEC return companies ranked anywhere between 350 to 600 by market capitalisation Rolling 12 months 84% 17% • The below graph compares th
Slide 22: AVR has out performed all major health care indices
AVR has out performed all major health care indices 160% Rolling 12 months 140% AVR May 2022 120% S&P/ASX Emerging Companies 100% 80% Stoxx Europe 600 Health Care 60% S&P Composite 1500 Health Care 40% 20% Dow Jones US Medical Equipment Index 0% NASDAQ Health -20% Care Index -40%
Slide 23: AVR outperformed major competitors
AVR outperformed major competitors Share price movement (8 April – 9 May 2022) 10% Anteris 5% Boston Scientific 0% -5% -10% Medtronic -15% Edwards Lifesciences -20% -25%
Slide 24: Top 40 investors hold 61% of the Company
Top 40 investors hold 61% of the Company OWNERSHIP COUNTRY SHAREHOLDER MIX AUSTRALIA 68% L1 CAPITAL SIO CAPITAL 8% 9% OTHER 1% OTHER TOP 40 NEW 30% ZEALAND UNITED PERCEPTIVE 4% STATES LIFE 27% SCIENCES 14% 70% INVESTOR TYPE HISTORY 60% 50% March 2021 40% 30% May 2022 20% OTHER SHAREHOLDERS 10% 39% 0
Slide 25: Financials only tell part of the story
Financials only tell part of the story
Slide 26: How do we compare?
How do we compare ?
Slide 27: What is our competitive advantage?
What is our competitive advantage ?
Slide 28: ADAPT + DurAVR + ComASUR
ADAPT® + DurAVR™ + ComASUR™ For lifetime management of Aortic Stenosis patients www.anteristech.com | Follow us @anteristech Copyright Anteris Technologies Ltd 2021
Slide 29: Slide 29
Slide 30: ADAPT the best anti calcification treatment in the world
ADAPT® the best anti calcification treatment in the world 1. Data on file, Admedus 2. Data on File, Admedus; AGRF DNA Extraction Reports (CAGRF16022 and CAGRF 15684), 2017 3. Neethling et al. Enhanced biostability and biocompatibility of decellularized bovine pericardium, crosslinked with an ultra-l
Slide 31: Slide 31
Slide 32: Aortic stenosis is a disease of calcification
Aortic stenosis is a disease of calcification Calcium deposits cause a narrowing of the valve opening and an increase in pressure Calcium build up in valve with stenosis
Slide 33: DurAVR: first and only 3D single piece TAVR valve
DurAVR™ – the first and only 3D single piece TAVR valve in the world • Designed to be anatomically correct Lasts Longer • Restores pre disease haemodynamics Works Better • Has greater structural integrity • Opens wider (80%)
Slide 34: Slide 34
Slide 35: Younger patients need new solutions that Last Longer and Work Better
Younger patients need new solutions that Last Longer and Works Better Younger patients need longer lasting next generation valve technology Younger Patient Age Key Considerations patients now eligible Valves now What Does Life Guidelines need to last Expectancy TAVR as class(I) for ages 65-80 this M
Slide 36: ComASUR Delivery System
ComASUR™ Delivery System a ANTERIS
Slide 37: Slide 37
Slide 38: Severe aortic stenosis requires the aortic valve to be replaced
Severe aortic stenosis requires the aortic valve to be replaced SAVR (Surgical Aortic Valve TAVR (Transcatheter Aortic Replacement) Valve Replacement)
Slide 39: Today's TAVRs need to address key medical needs
Current TAVR devices Todays TAVR’s need to address 4 key medical needs Current products fall short in two critical areas Predictable Optimal Low Incidence of Procedure Hemodynamic Durability Complications Performance Competitor products can start Competitor products leave the to deteriorate within 1
Slide 40: DurAVR THV satisfies all key areas
Current TAVR devices DurAVR™ THV satisfies all 4 key areas ComASUR™ delivery system is Better haemodynamics at rest DurAVR’s™ 3D uni-body design has greater more predictable with and during increased cardiac structural integrity + ADAPT® anti commissural alignment output (exercise) calcification tre
Slide 41: Slide 41
Slide 42: Current TAVR products were not designed for younger patients
Current TAVR products were not designed for younger patients 1st Generation TAVR’s designed to solve a different problem to today’s patients needs “Patient needs a valve that restores an active Patient needs a safe alternative to lifestyle for the rest of their life” open heart surgery” 1st and 2nd
Slide 43: Skate to where the puck is going
"Skate to where the puck is going not where it has been." — Wayne Gretzky
Slide 44: Before the breakthrough comes the trial
HUMAN BEFORE THE BREAKTHROUGH COMES THE TRIAL
Slide 45: Slide 45
Slide 46: DurAVR First-in-Human Study: Individual Patient Case Example
DurAVR™ First-in-Human Study: Individual Patient Case Example FIH 30-day DurAVR™ haemodynamics: • Area Derived Annulus Size 21.3mm • EOA = 2.02 cm2 • DVI = 0.66 • Intra-op Coaptation length = 10.3 mm EOA compared to annulus size matched benchmark*: • Sapien 3 = 1.41 cm2 +/- 0.27 • Evolut R = 1.66 cm
Slide 47: ComASUR: A unique physician designed delivery system
ComASUR™ A unique Physician designed delivery system Easy and Predictable Commissural Alignment • Intuitive handle design • Precise balloon expandable deployment • Unique ability to rotate valve at annular level for consistent, predictable commissural alignment
Slide 48: Near perfect laminar flow, unique in the valve space
Near perfect laminar flow, unique in the valve space Poor laminar flow observed in other products leads to early valve deterioration. == == DurAVR™ has perfect laminar flow!
Slide 49: We were successful in the most challenging patient group
We were successful in the most challenging patient group Severe Annular Calcium Extreme Leaflet Calcium Type 1 Bicuspid
Slide 50: DurAVR First-in-Human Study Challenging Anatomical Conditions Treated
DurAVR™ First-in-Human Study Challenging Anatomical Conditions Treated Severe Annular Extreme Leaflet Calcium Calcium Type 1 Bicuspid Baseline CTs
Slide 51: DurAVR - Commissural alignment
DurAVR™ - Commissural alignment Excellent Commissural Alignment & Leaflet Function 30-day CT
Slide 52: DurAVR different to the competitors by design
DurAVR™ Different to the competitors by design Unique Design of a Single Piece of Tissue 3D Molded to Mimic the Native Aortic Valve Anatomy • Designed in diastole (closed position) • Opens wider with less pressure • Remains open longer with the purpose of CURRENT VALVES improving haemodynamics * Dat
Slide 53: DurAVR THV: Outperforms the competitors in every regard
DurAVR™ THV: Outperforms the competitors in every regard DurAVR™ Computational Fluid Model* Diastole Systole Coaptation Modeling* • 85% greater coaptation area** • 35% lower leaflet strain** • Optimal laminar flow* *Data on file, Anteris **Lim KH et al., Flat or Curved Pericardial Aortic Valve Cusps
Slide 54: DurAVR 3D Single Piece THV with ADAPT
DurAVR™ 3D Single Piece THV with ADAPT® Exercise Capacity Durability Future Management Valve that restores near-normal haemodynamics Valve that lasts the lifetime of the patient Valve that allows for future intervention PROVEN TISSUE DURABILTY Superior anti-calcification tissue process (ADAPT®)* IMP
Slide 55: id people
id people y wanted, nave said er horse - Henry Ford
Slide 56: In the end its all about patients
In the end its all about patients
Slide 57: Next cohort of patients being implanted now
Next cohort of patients being implanted now !
Slide 58: Tbilisi, Georgia first-in-human
ANTERIS TECHNOLOGIES A Structural Heart Company TBILISI, GEORGIA, 25/5/22. FIH.
Slide 59: Market opportunity
Market opportunity
Slide 60: AVR Market Growth
AVR Market Growth • USD 14 billion by 2028 • US CAGR 12% • US 42% of the market in 2021 • 75% of AVR will be TAVR by 2028
Slide 61: The Global TAVR market will continue to show strong growth
The Global TAVR market will continue to show strong growth into the future TAVR PROCEDURES 2020 -2028 TAVR REVENUE 2020 -2028 US OUS US OUS CAGR US 11.4% CAGR OUS 9% USD Billions 242 229 $9 215 $9 202 $8 190 $8 174 $7 $7 154 $6 134 $5 118 $4 165.73 174.78 145.9147 155.7 $5 122.4052 136.0115 $4 $5 $5
Slide 62: TAVR/SAVR Regional Market share
TAVR/SAVR Regional Market share 2021 TAVR/Surgical Aortic TAVR Procedures by Stenosis Procedures EU TAVR Market Share 2021 Regions 2% 6% 225445, 42% 4% 10% 9% Edwards 43% Medtronic Edwards Boston Abbott Others 45% 39% Medtronic TAVR EU 305580, 58% Surgery US US TAVR Market Share 2021 5% 42% Medtroni
Slide 63: 2021 TAVR Market Share US EU
2021 TAVR Market Share US EU US Market TAVR Share 2021 EU TAVR Market Share 2021 5% 2% 6% 10% 31% 43% 64% 39% Edwards Medtronic Boston Abbott Others Edwards Medtronic Abbott
Slide 64: 2021 to 2028 TAVR vs Surgical Procedures: US
2021 to 2028 TAVR vs Surgical Procedures: US 2028 US TAVR/Surgical Aortic Stenosis Procedures 2021 US TAVR/Surgical Aortic Stenosis Procedures 56404, 24% 81079, 47% 90960, 53% 174780, 76% TAVR Total Surgical (no TAVR) TAVR Total Surgical (no TAVR)
Slide 65: 2021 Global Procedures vs Revenue
2021 Global Procedures vs Revenue Global 2021 TAVR Surgical Aortic Stenosis Procedures Global 2021 TAVR Surgical Revenue US$ 1,124,450,988.13 , 18% 225445, 42% 305580, 58% 5,241,724,662.90 , 82% TAVR Total Surgical (no TAVR) TAVR Total (excl TAVR)
Slide 66: Key Partnerships
Key Partnerships • Anteris has entered key Academic partnerships with the following: • Yale University • Columbia University • UWA
Slide 67: Partnerships for next generation valve materials
We are also engaged in partnerships for next generation valve materials • Currently Anteris is actively researching two distinct technologies that will allow us to replicate the design benefits of the DurAVR™ valve in new materials The company has entered multiple partnerships researching alternate
Slide 68: Future Revenues
| Future Revenues
Slide 69: First TAVR revenues in 2023
First TAVR revenues in 2023 • Anteris TAVR studies will potentially qualify as a Category B study • Anteris will commence supplying product during its FDA studies at approx USD25k per unit • First TAVR revenues will commence in 2023
Slide 70: Key presentations
| * Key presentations
Slide 71: DurAVR will be featured at key medical conferences in 2022
DurAVR™ will be featured at key medical conferences in 2022 Q1 Q2 Q3 Q4 Feb 26-Mar 1 May 17-20 June 8-11 Sep 16-20 Nov 27-29 Washington DC Pairs Chicago Boston London 2022 JAN Feb MAR APR MAY JUN JUL AUG SEP OCT NOV DEC Podium: Podium: Podium: Podium: Podium: Innovation PCR Innovation Submitted: New
Slide 72: Slide 72
Slide 73: Questions
Questions • Market valuation • When can we start selling DurAVR™ • Nasdaq listing progress/structure • Development milestones • FIH TAVR • SAVR study • EFS FDA study • R&D Further developments
Slide 74: Slide 74
Slide 75: Slide 75
Slide 76: Board of Directors
Board of Directors John Seaberg Wayne Paterson Stephen Denaro Wenyi Gu Director and Chair Director and Director and Director Chief Executive Officer Company Secretary 76
Slide 77: Executive Team
Executive Team David St. Denis Matthew McDonnell Christopher Meduri Chief Operating Officer Chief Financial Officer Chief Medical Officer 77
Slide 78: Anteris is supported by highly qualified advisors
Anteris is supported by highly qualified advisors Bernard Prendergast, MD Samir Kapadia, MD Gorav Ailawadi, MD Guy’s & St. Thomas’ Michael Reardon, MD Karl Poon, MBBS Jayme Bennetts, BMBS Cleveland Clinic Univ of Virginia Charlottesville, VA Nicolas Van Mieghem, MD London, UK (A/S) Houston Methodist
Slide 79: Anteris has a highly talented and engaged team
Anteris has a highly talented and engaged team
Slide 80: A great team in the right locations
A great team in the right locations Exceptional individuals doing exceptional things USA Europe APAC Innovation Centre & Corporate HQ (Minneapolis, USA) Biologics Manufacturing / R&D Strategic Hub in Europe (Malaga, Australia) (Geneva, Switzerland) Finance & IT Team (Brisbane, Australia) Confidentia
Slide 81: Lasts Longer, Works Better
ANTERIS CHNOLOGIES A Structural Heart Lasts Longer, Works Better A Valve Designed for Life. DurAVR’ TRANSCATHETER HEART VALVE SYSTEM
Anteris Technologies — Shareholder Meeting (May 2022) on 6ix